Arrival of biosimilars is expected to deliver savings of more than €100m over the four-year life of the agreement

The Irish healthcare system must do more to encourage competition by generic and biosimilar drugs if it is to cut Ireland’s drug bill and provide fund(...)

 Industry sources say the State  lost between €4 million and €5 million by the delay in reducing the price of Pfizer’s  blockbuster arthritis drug  Enbrel. Photograph: Paul Faith/AFP/Getty Images

The introduction of a biosimilar drug into the Irish market will save the Health Service Executive (HSE) millions of euro this year alone. In Septem(...)

Pfizer’s  Enbrel lost patent protection in Europe earlier this year. Biogen introduced Benepali into the Irish market in September

The price of one of the world’s most popular drugs is falling 30 per cent in Ireland under the terms of a recently signed pricing agreement. Enbrel,(...)

The HEA has written to Minister for Health Simon Harris expressing its concern over what it calls the “biosimilar blocker”. Photograph: Dave Meehan

The Health Services Executive could lose out on savings of more than €50 million a year on just three widely used drugs under the terms of the new Med(...)

 Minister for Health Simon Harris:  in the letter sent to him the Healthcare Enterprise Alliance says the pricing agreement includes “artificial pricing thresholds”. Photograph: Dave Meehan

Promised savings to the State’s bill for prescription drugs will not materialise under a new pricing agreement to be announced imminently, it has bee(...)